Royalty Pharma plc Class A Ordinary Shares (RPRX)
Stock · NASDAQ · Health Care
$60.97as of 10/16/2026
Price chart
Active signals
RPRX Signal Track Record
How signals performed across all stocks →What RPRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +1.7% | 60% | September 8, 2026 |
| Bollinger Band Breakdown | 24 | +0.3% | 54% | October 6, 2026 |
| Bollinger Band BreakoutActive now | 23 | +0.7% | 52% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +0.1% | 54% | October 11, 2024 |
| Any 20-session window (baseline) | +0.6% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 100
- Website
- www.royaltypharma.com/
Fundamentals
- 1-day range
- $55.72$57.08
- Market cap
- $32.97B
- P/E (trailing)
- 41.57
- P/E (forward)
- 9.82
- EPS (trailing)
- $1.46
- Dividend yield
- 2.96%
- Beta
- 0.39
- Avg. volume
- 2.93M
- Ex-dividend date
- August 14, 2026
- Dividend pay date
- September 10, 2026
How Royalty Pharma plc Class A Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 11, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Royalty Pharma plc Class A Ordinary Shares Competitors
Chosen by industry and closest market cap.
- RPRXRoyalty Pharma plc Class A Ordinary Shares$60.96▲ 2.25%Market cap $32.97BP/E 41.57$35.23$64.38
- ZTSZoetis Inc. Class A Common Stock$79.38▲ 1.22%Market cap $32.39BP/E 12.43$68.77$148.3
- ONCBeOne Medicines Ltd. American Depositary Shares$369.06▼ 1.34%Market cap $36.67BP/E 61.27$205.51$319.24
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$231.83▼ 0.94%Market cap $28.92BP/E 37.17$197.81$495.55
- INSMInsmed Incorporated Common Stock$96.27▼ 2.96%Market cap $28.73BP/E —$90.39$212.75
- TEVATeva Pharmaceutical Industries Limited American Depositary Shares$41.5▲ 0.95%Market cap $40.56BP/E 68.57$6,207$12,990
- ROIVRoivant Sciences Ltd. Common Shares$33.53▼ 1.50%Market cap $25.38BP/E —$15.9$42.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RPRX Royalty Pharma plc Class A Ordinary Shares | $32.97B | 41.57 | $60.96 | ▲ 2.25% | $35.23$64.38 |
| ZTS Zoetis Inc. Class A Common Stock | $32.39B | 12.43 | $79.38 | ▲ 1.22% | $68.77$148.3 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 61.27 | $369.06 | ▼ 1.34% | $205.51$319.24 |
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $28.92B | 37.17 | $231.83 | ▼ 0.94% | $197.81$495.55 |
| INSM Insmed Incorporated Common Stock | $28.73B | — | $96.27 | ▼ 2.96% | $90.39$212.75 |
| TEVA Teva Pharmaceutical Industries Limited American Depositary Shares | $40.56B | 68.57 | $41.5 | ▲ 0.95% | $6,207$12,990 |
| ROIV Roivant Sciences Ltd. Common Shares | $25.38B | — | $33.53 | ▼ 1.50% | $15.9$42.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026Yahoo · 10/9/2026
- Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates AgainYahoo · 10/8/2026
- Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67Benzinga · 10/7/2026
- Revolution Medicines: Priced For A Label The Trial Didn't Test; HoldSeekingAlpha · 10/3/2026
- Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?Yahoo · 10/1/2026
- If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much TodayBenzinga · 9/29/2026
- Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy ShiftsYahoo · 9/25/2026
- Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?Yahoo · 9/25/2026
- Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisitionbenzinga · 6/29/2026
Insider Activity
Insider Actions →- Marshall Urist · October 5, 2026 · Sale4.1K @ $57.1
- Christopher Hite · September 22, 2026 · Sale3.9K @ $58.93
- Christopher Hite · September 22, 2026 · Sale96.1K @ $58.51
- Christopher Hite · August 19, 2026 · Gift16.8K
- Christopher Hite · August 18, 2026 · Sale100.0K @ $59.97
- Terrance P. Coyne · August 13, 2026 · Sale9.2K @ $58.59
- Terrance P. Coyne · August 13, 2026 · Sale1.8K @ $59.14
- Marshall Urist · August 7, 2026 · Gift3.0K
- Terrance P. Coyne · August 7, 2026 · Gift18.5K
- Pablo G. Legorreta · August 7, 2026 · Gift30.0K
- Terrance P. Coyne · August 5, 2026 · Grant11.0K
- Christopher Hite · August 5, 2026 · Grant11.0K
- Pablo G. Legorreta · August 5, 2026 · Grant65.2K
- Marshall Urist · August 5, 2026 · Grant8.3K
- Marshall Urist · July 1, 2026 · Sale9.1K @ $55.88
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.